For pharmaceutical manufacturers handling cytotoxic taxanes, Docetaxel 20 mg/ml Concentrate for solution for infusion Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a sterile, non-aqueous, single-use concentrate in which docetaxel anhydrous is present at 20 mg/ml. The active substance, a semisynthetic taxane derived from 10-deacetylbaccatin III, is (2R,3S)-4-acetoxy-1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2,13α-diyl 4-acetate 2-benzoate 13-[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate], with molecular formula C43H53NO14, relative molecular mass 807.88 g/mol, and CAS registry number 114977-28-5. Pharmacopoeial evaluation is conducted against Ph. Eur. monograph 2544 for docetaxel trihydrate and the corresponding USP monograph where applicable, using HPLC assay and related substances under Ph. Eur. 2.2.29 and USP <621>, bacterial endotoxins under Ph. Eur. 2.6.14 or USP <85>, particulate matter under Ph. Eur. 2.9.19 or USP <788>, sterility under Ph. Eur. 2.6.1 or USP <71>, residual solvents according to ICH Q3C, and elemental impurities according to ICH Q3D. No manufacturer-specific model designation is included in this product identification; the item is defined by concentration, dosage form, and pharmacopeial grade, and any supplier-specific code should be cross-referenced in the certificate of analysis.

At production scale, the non-aqueous concentrate exhibits higher viscosity than aqueous parenteral solutions because of the polysorbate 80 and ethanol vehicle. Aseptic filling lines should therefore be qualified with media fills matched to the same viscosity, and product-contact surfaces must be polyolefin, polypropylene, glass, or stainless steel. Contact with PVC is avoided because the solubilising vehicle can extract di(2-ethylhexyl) phthalate. Final infusion preparation is performed by dilution into 0.9% sodium chloride injection or 5% glucose injection in PVC-free polyolefin or glass containers, with a nominal docetaxel concentration between 0.3 mg/ml and 0.74 mg/ml to reduce precipitation risk. For oral solid-dose manufacturing, the docetaxel API can be incorporated into tablets, capsules, granules, or oral dosage forms, but the 20 mg/ml concentrate itself is an injectable-grade liquid. Direct compression of crystalline docetaxel is limited by low aqueous solubility and content uniformity risk at low unit doses; published data for direct compression from this concentrate are limited, and formulation conversion is required.

What Distinguishes the 20 mg/ml Concentrate from Lyophilized Docetaxel Injection and Bulk API?

The 20 mg/ml concentrate differs from lyophilized docetaxel powder by eliminating the reconstitution step, which reduces foaming and the dosing error associated with over-reconstitution, while retaining a non-aqueous vehicle that requires controlled dilution. A lyophilized docetaxel presentation may contain docetaxel trihydrate and a separate diluent vial of 13% ethanol in water; the concentrate described here already contains the solubilising system, so the operator performs a single dilution rather than a two-step preparation. Both presentations must be diluted into PVC-free polyolefin or glass infusion vessels to avoid plasticizer leaching. The ethanol content of the concentrate imposes handling and disposal controls because docetaxel is classified as a hazardous drug under NIOSH criteria and should be handled according to USP <800>. Compared with bulk docetaxel API powder, the concentrate is not a direct tableting feedstock; it is a sterile liquid form that requires solvent removal, spray drying, lyophilisation, or formulation into solid dispersion for capsule or granule applications. The concentrate also differs from protein-bound paclitaxel nanoparticles, which use albumin as a carrier, whereas this docetaxel concentrate uses polysorbate 80 and ethanol; this difference influences downstream surfactant load, filter compatibility, and oral solid-dispersion design.

Container closure integrity is controlled by validated leak testing under USP <1207>, and 21 CFR 211.94 requires that container closures not be reactive, additive, or absorptive so as to alter safety, identity, strength, quality, or purity. For cytotoxic liquid products, elastomeric closures are typically fluoropolymer-coated butyl rubber stoppers with aluminium seals. The bacterial endotoxin limit for the parenteral concentrate is calculated as K/M, where K is 5 EU/kg/h for intravenous products and M is the maximum recommended dose expressed in mg/kg/h; the resulting limit is expressed in EU/mg and should be stated in the product specification. Sterility assurance for this non-aqueous concentrate relies on aseptic filtration and aseptic processing because terminal sterilisation is not feasible owing to thermal degradation of the taxane side chain. Filtration through a 0.22 µm sterilising-grade membrane should be validated under ASTM F838-20 or equivalent, with bacterial retention demonstrated in the polysorbate 80 and ethanol vehicle, because surfactant-containing formulations can reduce filter throughput and alter bubble-point values.

Physicochemical Stability and Critical Processing Limits in Oral and Injectable Formulation

Docetaxel is a lipophilic BCS Class IV compound with aqueous solubility reported below 10 µg/ml at 25 °C and log P near 4.1; formulation into oral granules, capsules, or tablets therefore requires solubilisation, amorphisation, or lipid-based delivery. Hot-melt extrusion with copovidone and vitamin E TPGS can produce amorphous solid dispersions, but processing temperature must remain below the thermal degradation onset established by the supplier’s thermogravimetric profile. High-shear granulation, extrusion-spheronisation, and capsule filling require dedicated containment isolators because docetaxel is cytotoxic; cleaning verification should be based on surface sampling and a health-based exposure limit established for the site. Particle size reduction by jet milling or wet milling should be controlled to the range selected in the validated formulation, and the solid state should be confirmed by X-ray powder diffraction because amorphous conversion may increase dissolution but reduce physical stability. Dissolution testing for oral docetaxel formulations should be discrimination-based and conducted under USP <711> using apparatus selection and media justified by solubility data; published methods frequently include surfactant to achieve sink conditions. Without a bioavailability enhancer, simple oral tablets or capsules are not bioequivalent to intravenous infusion because docetaxel undergoes first-pass metabolism by CYP3A4 and efflux by P-glycoprotein.

After dilution of the 20 mg/ml concentrate into 0.9% sodium chloride injection or 5% glucose injection in polyolefin containers, chemical and physical in-use stability should be established according to ICH Q1A and the licensed label. The diluted solution must not be frozen, and contact with alkaline solutions should be avoided because docetaxel degrades via base-catalysed hydrolysis of the ester side chain. The final infusion concentration should not exceed 0.74 mg/ml to reduce the risk of precipitation; lower concentrations may be required if visible precipitation or distribution system pressure indicates instability. Use of in-line filters with a pore size not greater than 0.22 µm may be required for infusion of diluted concentrate, and the filter material should be low-protein-binding polyethersulfone or equivalent, not PVC-containing.

When Oral Granulation and Capsule Filling Are Required for Cytotoxic Taxane APIs

Drug product manufacturing for oral docetaxel requires separation of the cytotoxic API from the general pharmaceutical facility. Granulation should be performed in isolator-based high-shear mixers with wash-in-place capability, and the granulating fluid should be selected for compatibility with docetaxel and the non-aqueous excipients used in the concentrate. Solvent-based granulation may require explosion-proof equipment if ethanol is carried into the granulation step. Capsule filling of docetaxel-containing granules should use containment-compatible machines such as dosator or tamping-pin encapsulation systems fitted with local exhaust ventilation; batch-to-batch content uniformity should be monitored under ICH Q2(R1) and USP <905>. For tablet compression, tooling and compression force should be selected to achieve target hardness while minimising sticking, and compaction data should be generated with instrumented tablet presses to identify elastic recovery and ejection force. Because docetaxel is highly potent, cleaning validation must include swab and rinse recovery studies using a validated analytical method with a limit of quantification below the acceptable residue limit.

For injectable finished-product manufacturing, the 20 mg/ml concentrate is typically filled aseptically into glass vials closed with fluoropolymer-coated butyl rubber stoppers and aluminium seals. Terminal sterilisation is not practical because docetaxel degrades under thermal stress. Filling-line transfer should use low-shear positive displacement or peristaltic pumps with platinum-cured silicone tubing, and hold time in stainless steel or glass should be validated to show no change in assay, related substances, and particulate matter. The concentrate is not intended for direct administration without dilution, and the final infusion container must be polyolefin or glass; PVC bags and PVC-containing administration sets are incompatible because polysorbate 80 can leach di(2-ethylhexyl) phthalate. The product should be stored below 25 °C, protected from light, and not frozen; storage at 2–8 °C may be required if the stability profile supports refrigerated holding.

Docetaxel shares the taxane mechanism of microtubule stabilisation with paclitaxel, but docetaxel is semisynthetic and binds to β-tubulin with higher affinity and distinct cellular retention. The 20 mg/ml concentrate differs from paclitaxel and nab-paclitaxel presentations in excipient composition and solvent load, and these differences influence extractable and leachable profiles, filter compatibility, and occupational exposure banding. In pharmaceutical product development, the selection between docetaxel concentrate, lyophilized docetaxel powder, and bulk docetaxel API should be based on the intended dosage form, aseptic processing capability, containment infrastructure, and the validated analytical package. For capsule and tablet development, the bulk API or a converted solid dispersion from the concentrate may be used; for injectable manufacture, the ready-to-dilute concentrate reduces reconstitution errors but requires ethanol-compatible transfer systems and PVC-free infusion materials. Published data for specific tablet, capsule, and granule formulations prepared directly from this concentrate are limited, so each formulation should be supported by stability-indicating assay, dissolution, and solid-state characterisation under ICH Q1A and ICH Q6A.